Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genprex, Inc. stock logo
GNPX
Genprex
$2.12
-4.1%
$3.46
$2.09
$42.40
$4.05M-0.6171,465 shs8,420 shs
MusclePharm Co. stock logo
MSLP
MusclePharm
$0.00
$0.00
$0.00
$7K-0.0726,442 shsN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
$3.85
$3.51
$2.50
$4.42
$6.72M-0.123,200 shsN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
$2.06
$1.26
$4.26
$8.11M0.98162,968 shs2,579 shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genprex, Inc. stock logo
GNPX
Genprex
-4.33%0.00%-26.33%-75.75%-93.24%
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00%0.00%0.00%0.00%-53.85%
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00%+1.32%-3.75%-2.04%+5.48%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genprex, Inc. stock logo
GNPX
Genprex
4.2793 of 5 stars
3.55.00.04.70.60.81.3
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genprex, Inc. stock logo
GNPX
Genprex
3.00
Buy$10.00371.70% Upside
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest RELV, MSLP, TRIL, REXN, and GNPX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Genprex, Inc. stock logo
GNPX
Genprex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/25/2024
Genprex, Inc. stock logo
GNPX
Genprex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$10.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genprex, Inc. stock logo
GNPX
Genprex
N/AN/AN/AN/A$4.99 per shareN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
$50.04M0.00N/AN/A($0.94) per share0.00
Reliv' International, Inc. stock logo
RELV
Reliv' International
$35.06M0.19$0.09 per share44.53$6.36 per share0.61
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/A$2.48 per shareN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genprex, Inc. stock logo
GNPX
Genprex
-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)
MusclePharm Co. stock logo
MSLP
MusclePharm
-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
-$440KN/AN/AN/A-0.61%-1.89%-1.31%N/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
-$8.64MN/A0.00N/AN/AN/A-72.60%-55.68%N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genprex, Inc. stock logo
GNPX
Genprex
N/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/A
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genprex, Inc. stock logo
GNPX
Genprex
N/A
2.31
2.31
MusclePharm Co. stock logo
MSLP
MusclePharm
N/A
0.25
0.23
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.05
1.70
1.04
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
N/A
3.37
3.37
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Genprex, Inc. stock logo
GNPX
Genprex
14.05%
MusclePharm Co. stock logo
MSLP
MusclePharm
15.49%
Reliv' International, Inc. stock logo
RELV
Reliv' International
7.95%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
7.49%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%

Insider Ownership

CompanyInsider Ownership
Genprex, Inc. stock logo
GNPX
Genprex
11.54%
MusclePharm Co. stock logo
MSLP
MusclePharm
60.70%
Reliv' International, Inc. stock logo
RELV
Reliv' International
31.18%
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
1.10%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
9.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Genprex, Inc. stock logo
GNPX
Genprex
261.91 million1.69 millionOptionable
MusclePharm Co. stock logo
MSLP
MusclePharm
2733.39 million13.12 millionNot Optionable
Reliv' International, Inc. stock logo
RELV
Reliv' International
911.75 millionN/ANot Optionable
Rexahn Pharmaceuticals, Inc. stock logo
REXN
Rexahn Pharmaceuticals
54.48 millionN/AOptionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

RELV, MSLP, TRIL, REXN, and GNPX Headlines

SourceHeadline
Cachet Bicycle shakes off COVIDCachet Bicycle shakes off COVID
baytoday.ca - February 25 at 12:23 PM
Rejuvenate your look with a trip to Fourth Avenue Medical AestheticsRejuvenate your look with a trip to Fourth Avenue Medical Aesthetics
chch.com - January 30 at 5:32 PM
TTI apprehends motorists for illegal removal of clamps, hunt for four others underwayTTI apprehends motorists for illegal removal of clamps, hunt for four others underway
bulawayo24.com - January 30 at 5:32 PM
BridgeBio raises $1.25bn, and other biotech financingsBridgeBio raises $1.25bn, and other biotech financings
pharmaphorum.com - January 19 at 7:18 AM
Ratio Therapeutics Raises $50M in Series B FinancingRatio Therapeutics Raises $50M in Series B Financing
precisionmedicineonline.com - January 17 at 1:39 PM
Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com
businesswire.com - November 10 at 1:22 PM
Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 8 at 1:30 AM
The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period
uk.finance.yahoo.com - July 31 at 9:03 AM
Ratio Therapeutics unveils new research and development facilityRatio Therapeutics unveils new research and development facility
biopharma-reporter.com - May 15 at 10:33 AM
WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: Can Cause Even DeathWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'
msn.com - April 26 at 12:18 AM
Leukemia Therapeutics Global Market Report 2023Leukemia Therapeutics Global Market Report 2023
uk.finance.yahoo.com - April 4 at 10:35 AM
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
finance.yahoo.com - March 28 at 9:12 AM
Trillium House, an affordable housing project in Warrenton, close to completionTrillium House, an affordable housing project in Warrenton, close to completion
dailyastorian.com - January 10 at 12:26 AM
FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma
nz.finance.yahoo.com - October 19 at 9:39 AM
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
seekingalpha.com - September 14 at 9:48 AM
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of DirectorsZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
nz.finance.yahoo.com - September 12 at 7:55 AM
Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is NeededPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed
seekingalpha.com - August 17 at 11:07 AM
TTI reviews parking modelTTI reviews parking model
chronicle.co.zw - August 10 at 10:41 PM
TTI working round the clock to configure its systemsTTI working round the clock to configure its systems
chronicle.co.zw - August 10 at 10:41 PM
Pfizer in advanced talks to buy firm making sickle cell drugsPfizer in advanced talks to buy firm making sickle cell drugs
pmnewsnigeria.com - August 7 at 3:57 AM
10 Psychedelics CEOs To Pay Attention To In 202210 Psychedelics CEOs To Pay Attention To In 2022
markets.businessinsider.com - June 22 at 10:08 AM
Highlights from ASCO Annual Meeting 2022Highlights from ASCO Annual Meeting 2022
healio.com - June 15 at 1:37 PM
Chlormethine gel may be more effective than ointment for mycosis fungoidesChlormethine gel may be more effective than ointment for mycosis fungoides
healio.com - May 27 at 4:34 PM
Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?
edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Genprex logo

Genprex

NASDAQ:GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
MusclePharm logo

MusclePharm

OTCMKTS:MSLP
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
Reliv

Reliv' International

NASDAQ:RELV
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
Rexahn Pharmaceuticals logo

Rexahn Pharmaceuticals

NASDAQ:REXN
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Trillium Therapeutics logo

Trillium Therapeutics

NASDAQ:TRIL
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.